Abstract：
Osteonecrosis of the jaw is a recognized complication associated with bevacizumab. Here, we present a patient with squamous cell carcinoma of the tonsil who experienced minimal skin fibrosis following intensity-modulated radiation therapy. Subsequently, the patient developed rectal adenocarcinoma and encountered osteonecrosis of the jaw after receiving two cycles of bevacizumab. Close monitoring, accompanied by thorough examination to detect early signs of osteonecrosis of the jaw, should be considered for patients who have undergone radiation therapy in the head and neck region and are receiving bevacizumab or other medications known to be associated with osteonecrosis of the jaw.
摘要：
颌骨坏死是与贝伐单抗相关的公认并发症。这里,我们介绍了1例扁桃体鳞状细胞癌患者,在调强放疗后出现了轻微的皮肤纤维化.随后，患者在接受两个周期的贝伐单抗治疗后发展为直肠腺癌,并发生颌骨坏死.密切监测,伴随着彻底的检查，以发现颌骨坏死的早期迹象，对于在头颈部接受放射治疗并且正在接受贝伐单抗或其他已知与颌骨坏死相关的药物的患者，应考虑。
